A phase 1 study of N-acetylcysteine
Latest Information Update: 30 Oct 2020
At a glance
- Drugs Acetylcysteine (Primary)
- Indications Traumatic brain injuries
- Focus Adverse reactions
- 30 Oct 2020 New trial record
- 27 Oct 2020 According to an ATAI Life Sciences media release, the Neuronasal has been granted Investigational New Drug (IND) clearance by the FDA to continue phase I clinical trial development in partnership with ATAI Life Sciences.